Kahn Swick & Foti, LLC has initiated an investigation into the proposed sale of Penumbra, Inc. to Boston Scientific Corporation. The firm, led by former Louisiana Attorney General Charles C. Foti, Jr., is examining whether the merger consideration—comprising a cash payment alongside a specified equity exchange ratio—and the process leading to this agreement are fair to Penumbra shareholders. Investors are being invited to contact KSF’s managing partner, Lewis S. Kahn, to discuss potential legal claims regarding undervaluation of the company.

BTIG analysts revised their recommendation on Penumbra from Buy to Neutral after Boston Scientific announced its intent to acquire the company. While the deal implies a significant premium over Penumbra’s trading levels prior to the announcement, BTIG cited concerns over integration risks and potential dilution effects from the equity component of the transaction. The downgrade reflects caution about near-term returns for Penumbra investors as the deal progresses through shareholder and regulatory approvals.

Boston Scientific’s agreement to acquire Penumbra for approximately $14.5 billion is the largest deal it has pursued in roughly twenty years. The combination is expected to broaden Boston Scientific’s neurovascular and cardiovascular offerings, incorporating Penumbra’s thrombectomy and embolization platforms into its portfolio. The boards of both companies have approved the transaction, which is slated to close in calendar 2026, subject to customary closing conditions and Penumbra shareholder consent.